Celularity (CELU)
(Delayed Data from NSDQ)
$3.00 USD
-0.02 (-0.66%)
Updated Apr 29, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
CELU 3.00 -0.02(-0.66%)
Will CELU be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CELU based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CELU
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates
CELU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
Other News for CELU
Celularity Inc. to Host Investor and Analyst Research & Development Day
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Celularity receives Nasdaq notice regarding late Form 10-K filing
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products